By inhibiting NF-κB, activated PPARγ significantly reduced the expression of pro-inflammatory, pro-angiogenic, and pro-transfer signaling molecules in the TME, including IL-6, IL-8, CXCR4, MMP2, and MMP9, which further inhibited the activity of tumor cells in breast cancer (Papi et al., 2014; Rovito et al., 2016). This evidence concerns the gene NFKB1 and breast carcinoma.